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OBJECTIVES We evaluated the incidence, predictors, and treatment of pacemaker syndrome in patients
with sinus node dysfunction treated with ventricular-based (VVIR) pacing in the Mode
Selection Trial (MOST).
BACKGROUND Pacemaker syndrome, or intolerance to VVIR pacing, consists of cardiovascular signs and
symptoms induced by VVIR pacing.
METHODS The definition of pacemaker syndrome required that a patient with single-chamber VVIR
pacing develop either congestive signs and symptoms associated with retrograde conduction
during VVIR pacing or a 20 mm Hg reduction of systolic blood pressure during VVIR
pacing, associated with reproducible symptoms of weakness, lightheadedness, or syncope.
RESULTS Of 996 patients randomized to VVIR pacing, 182 (18.3%) met criteria for pacemaker
syndrome in follow-up. Pacemaker syndrome occurred early in most patients (13.8% at 6
months, 16.0% at 1 year, increasing to 19.7% at 4 years). Baseline univariate predictors of
pacemaker syndrome included a lower sinus rate and higher programmed pacemaker rate.
Previous heart failure, ejection fraction, and drop in systolic blood pressure with VVIR pacing
at implantation did not predict the development of pacemaker syndrome. Post-implantation
predictors of pacemaker syndrome were a higher percentage of paced beats, higher
programmed low rate, and slower underlying spontaneous sinus rate. Quality of life decreased
at the time of diagnosis of pacemaker syndrome and improved with reprogramming to
atrial-based pacing.
CONCLUSIONS Severe pacemaker syndrome developed in nearly 20% of VVIR-paced patients and improved
with reprogramming to the dual-chamber pacing mode. Because prediction of pacemaker
syndrome is difficult, the only way to prevent pacemaker syndrome is to implant atrial-based
pacemakers in all patients. (J Am Coll Cardiol 2004;43:2066–71) © 2004 by the American
College of Cardiology Foundationd
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bacemaker syndrome is defined as intolerance to
entricular-based (VVIR) pacing due to loss of atrioventric-
lar (AV) synchrony. Although there is no universal agree-
ent on the definition or diagnostic criteria of pacemaker
yndrome, symptoms include dyspnea on exertion, paroxys-
al nocturnal dyspnea, orthopnea, orthostatic hypotension,
nd even syncope (1–3). The incidence of pacemaker
yndrome in various studies ranges from 2% (4) to 83% (5),
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b003, accepted October 15, 2003.epending to a large degree on the diagnostic criteria. The
ode Selection Trial (MOST) (6,7) randomly assigned
atients with sick sinus syndrome to atrial-based (physio-
ogic) or VVIR pacing. Pacemaker syndrome was prospec-
ively defined and evaluated, thereby offering the opportu-
ity to determine the incidence and predictors of pacemaker
yndrome in a large clinical cohort.
See page 2072
ETHODS
atients. The principal eligibility criteria for the MOST
tudy included a clinical diagnosis of sick sinus syndrome
equiring implantation of a permanent pacemaker. A clin-
cal diagnosis of sick sinus syndrome was defined as one of
he following: 1) a documented symptomatic sinus pause
3 s; 2) an asymptomatic sinus pause5 s; 3) chronic sinus
radycardia with a heart rate 50 beats/min, accompanied
y symptoms of fatigue and dyspnea caused by chronotropic
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June 2, 2004:2066–71 Pacemaker Syndrome in the MOST Studyncompetence; or 4) sinus bradycardia with a heart rate50
eats/min that restricted the use of long-term medical
herapy that was deemed necessary for other medical con-
itions. Patients were eligible if they were age 21 years or
lder. The patient had to be eligible for a dual-chamber
acemaker utilizing a transvenous approach and to provide
ritten, informed consent. Exclusion criteria included clin-
cally overt congestive heart failure, chronic atrial fibrillation
ithout documented sinus mechanism within the previous
ix months, malignancy expected to limit the patient’s
ife-span during the course of the trial, severe psychiatric
llness that would limit compliance, or inadequate atrial or
entricular capture or sensing thresholds at the time of
acemaker implantation.
acemaker implantation. All patients received dual-
hamber pacemakers. After adequate atrial and ventricular
ensing and threshold parameters were achieved, patients
ere randomized to either rate-modulated VVIR or dual-
hamber (DDDR) pacing. At the time of pacemaker im-
lantation, the implanting physician recorded the presence
r absence of retrograde atrial activation during VVIR
acing at both 70 and 100 beats/min, as well as blood
ressure during native sinus rhythm and during VVIR
acing at heart rates 15 beats/min greater than the native
inus rhythm. Baseline quality-of-life measures, including
he 36-item Medical Outcome Study Short-Form (SF-36)
8), the specific activity scale (9), health utilities using the
ime tradeoff method (10), and self-reported quality of life
n a scale of 0 to 100 (11) were collected before pacemaker
mplantation. Initial recommended programming of the
acemaker included a lower rate of 60 beats/min, with rate
odulation adjusted to a heart rate of 90 to 110 beats/min
fter a 1-min brisk walk.
ollow-up. Follow-up was performed at one, three, and six
onths after pacemaker implantation and then every six
onths. Follow-up data included the interim clinical his-
ory, physical examination, pacemaker interrogation, and
uality-of-life status. The primary end point of the MOST
tudy was the first occurrence of stroke or death.
A secondary end point and the focus of the current
nalysis was the incidence of pacemaker syndrome. In the
OST study, pacemaker syndrome was defined by: 1) new
r worsened dyspnea, orthopnea, elevated jugular venous
ressure, rales, and edema with ventriculoatrial (VA) con-
Abbreviations and Acronyms
AV  atrioventricular
CTOPP  Canadian Trial of Physiologic Pacing
CI  confidence interval
DDDR  dual-chamber pacing
HR  hazard ratio
MOST  Mode Selection Trial
SF-36  36-item Short Form
VA  ventriculoatrial
VVIR  ventricular-based (pacing)uction during ventricular pacing; or 2) symptoms of
izziness, weakness, presyncope or syncope, and a 20 mm
g reduction of systolic blood pressure when the patient
ad VVIR pacing compared with atrial pacing or sinus
hythm (performed during follow-up evaluation).
When pacemaker syndrome was diagnosed at the clinical
ite, investigators were required to discuss the case with the
linical Coordinating Center. Before crossover from VVIR
o DDDR, investigators were encouraged to pace the
entricle at a lower rate and/or to decrease the aggressive-
ess of the sensor-driven rate. If symptoms did not resolve,
hey were required to call the principal investigator of the
tudy, who reviewed the indications for crossover. Before
nd after crossover, patients were evaluated using the SF-36,
he specific activity scale, the time tradeoff approach, and
he self-reported 0 to 100 scale.
tatistical methods. The association of baseline and im-
lant variables and discharge medications with the risk of
acemaker syndrome was assessed using a single-predictor
ox proportional hazards model for each variable. The
odel for heart rate contained a linear spline, which allowed
different risk relationship below and above 55 beats/min.
or baseline and implant variables, all 996 VVIR patients
ere included. For discharge medications, all patients who
id not meet the criteria for pacemaker syndrome in the
ospital were included (n  961). The Kaplan-Meier
ethods were used to estimate six-month event rates for
ubgroups defined by baseline and implant variables.
Because analysis of variables that are measured repeatedly
ver time is inherently complex, descriptive statistics and
ormal hypothesis tests for the association of follow-up
ariables with pacemaker syndrome risk employed two
ifferent approaches. For descriptive statistics, follow-up
ata from before the onset of pacemaker syndrome were
sed for patients who developed it; for patients who did not
evelop pacemaker syndrome, follow-up data from the first
96 days were used, as this was the third quartile of time to
acemaker syndrome and represented the time span during
hich patients were at greatest risk of developing pacemaker
yndrome. Variables were defined for each patient as fol-
ows: mean value of reported intrinsic heart rates, total
ercentage of beats that were VVIR paced, total percentage
f beats paced at 90 beats/min or higher, programmed low
ate at which the patient spent the most time, and presence
f VA conduction reported at any time. The association of
hese variables with risk of pacemaker syndrome was for-
ally assessed in patients who did not develop pacemaker
yndrome in the hospital and whose follow-up included at
east one visit while in VVIR pacing, using separate Cox
roportional hazards models with the variable of interest
ntered as a time-dependent co-variate. These models allow
atients’ values for these co-variates to change over the
ourse of the follow-up period. All follow-up data were used
n these models. Approximately 800 patients were included
n this analysis, but the number differed by variable, depend-
ng on the extent of missing data. Assessments for VA
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Pacemaker Syndrome in the MOST Study June 2, 2004:2066–71onduction after randomization were performed only in
atients who were suspected of having pacemaker syn-
rome; because of the bias in this sample, summary statis-
ics, but no significance tests, are presented for VA conduc-
ion during follow-up.
Baseline and follow-up variables that were significant in
nivariate tests were entered into a multivariable Cox
roportional hazards model. A backward selection proce-
ure was used to identify independent predictors.
Changes in quality of life before and after crossover were
ested utilizing the paired nonparametric Wilcoxon signed-
ank test. These analyses were restricted to patients who
rossed over during the first year of follow-up and who had
uestionnaires obtained at baseline, before crossover, and
fter crossover.
ESULTS
atient characteristics. There were 2,010 patients with
inus node dysfunction randomized, of whom 996 were
ssigned to single-chamber, rate-modulated VVIR pacing.
f those randomized to VVIR pacing, 477 (48%) were
emale, and the median age was 74 years. New York Heart
ssociation functional class III or IV heart failure was
resent at baseline in 145 patients (15%). Of the 996
atients, 209 (21%) had concurrent AV block and 52 (5%)
ad a history of complete heart block.
acemaker syndrome. Among VVIR patients, 182
18.3%) met criteria for pacemaker syndrome, as defined by
he study protocol. Forty-one patients met definition 1 only,
Figure 1. Kaplan-Meier graph showing the time from implantation to time4 met definition 2 only, and 77 met definitions 1 and 2, as siscussed earlier. By life-table analysis, the incidence of
acemaker syndrome was 13.8% at six months, 16.0% at one
ear, 17.7% at two years, 19.0% at three years, and 19.7% at
our years (Fig. 1).
aseline and implant data. The incidence of pacemaker
yndrome was similar regardless of the criterion by which
patient was defined as having sick sinus syndrome.
owever, a slower sinus rate at the time of implantation
as associated with the development of pacemaker syn-
rome. The hazard ratio (HR) for developing pacemaker
yndrome was 1.11 (95% confidence interval [CI] 1.04 to
.19, p  0.01) for each 5-beat/min decrease in patients
ith baseline heart rates above 55 beats/min. For heart
ates below 55 beats/min, further reductions in sinus rates
ere not predictive of the development of the pacemaker
yndrome (p  0.9). A higher programmed ventricular
ate was associated with the development of pacemaker
yndrome, with a HR of 1.15 (95% CI 1.04 to 1.26) for
ach 5-beat/min increase in the programmed rate (p 
.005). No other patient characteristic before or at
mplantation, including age, gender, left ventricular ejec-
ion fraction, presence or absence of VA conduction,
ystolic blood pressure drop with VVIR pacing at im-
lantation, and duration of QRS or PR intervals, was
ssociated with the development of pacemaker syndrome
Table 1).
ischarge medications. There was no association between
se of beta-blockers, calcium antagonists, or amiodarone at
ospital discharge and the risk of subsequent pacemaker
rmanent crossover for pacemaker syndrome. The y-axis is truncated at 0.7.yndrome.
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June 2, 2004:2066–71 Pacemaker Syndrome in the MOST Studyollow-up data. The risk of pacemaker syndrome was
ignificantly higher in patients with a higher percentage
f ventricular paced beats (p  0.0001; HR 1.22 [95% CI
.16 to 1.28] for each 10% increase), a higher pro-
rammed, lower pacemaker rate (p  0.0001; HR 1.27
95% CI 1.16 to 1.38] for 5-beat/min increase), and a
lower underlying sinus heart rate (p  0.0005; HR 1.09
95% CI 1.04 to 1.15] for 5-beat/min decrease) (Table
). The presence of chronotropic incompetence, as doc-
mented by having fewer native beats at a rate 90
eats/min, showed a trend toward increased risk of
acemaker syndrome (p  0.060, HR 1.07 [95% CI 0.99
o 1.14] for a 5% decrease).
Table 1. Association of Baseline Variables Wit
Analysis
Variable* N
Sinus heart rate at implant (beats/min)
60
60
Age (yrs)
75
75
Gender
Female
Male
VA conduction at 70 beats/min
Present
Absent
VA conduction at 100 beats/min
Present
Absent
NYHA CHF class
III and IV
I and II
Systolic blood pressure drop with V-pacing
13
13
Programmed low rate (beats/min)
65
50–60
45
Prior atrial fibrillation or flutter
Yes
No
*Continuous variables were categorized for the purpose of gen
Cox models as continuous.
K-M  Kaplan-Meier; NYHA CHF  New York Hear
Table 2. Association of Follow-Up Variables W
Variable Pacemaker S
Sinus rate (beats/min) 57.2 (1
% beats paced  90 beats/min 8.9 (1
% beats V-paced 58.1 (3
Programmed low rate (beats/min)
65 21%
50–60 77%
45 2%
The p values are derived from separate Cox models that incl
as mean (SD) or %.NA  not applicable; VA  ventriculoatrial.ultivariate model. Of the univariate predictors of pace-
aker syndrome (baseline and follow-up sinus rate, pro-
rammed low rate, percentage of beats paced, and percent-
ge of beats paced at 90 beats/min were entered into the
ultivariate model), only a higher percentage beats paced
as an independent predictor (p  0.0001; HR 1.22 [95%
I 1.16 to 1.28] for each 10% increase). A programmed
ower rate, the second most important factor, made a
arginal and nonsignificant contribution to the predictive
odel (p  0.073; HR 1.11 [95% CI 0.99 to 1.23] for a
-beat/min increase).
uality of life. At the time of diagnosis of pacemaker
yndrome, quality of life was lower than that at the time of
sk of Pacemaker Syndrome: Univariate
r 6-Month K-M Rate (%) p Value
17.4 0.003
10.5
14.2 0.73
13.3
13.9 0.51
13.7
15.6 0.70
13.9
14.2 0.34
12.3
18.0 0.13
13.2
14.9 0.34
12.9
19.9 0.005
12.4
10.7
17.0 0.08
20.5
Kaplan-Meier rates for subgroups, but were included in the
ciation congestive heart failure class; VA  ventriculoatrial.
Risk of Pacemaker Syndrome
ome No Pacemaker Syndrome p Value
61.7 (14.2) 0.0005
11.4 (12.6) 0.060
47.9 (33.7) 0.0001
16% 0.0001
79%
5%
e variables as time-dependent covariates. Data are presentedh Ri
umbe
475
515
503
493
477
519
220
389
249
457
145
841
388
456
174
785
28
440
556
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Pacemaker Syndrome in the MOST Study June 2, 2004:2066–71mplantation for nine of the 10 SF-36 scales and was
ignificantly worse for six of these scales (data based on 80
atients) (Table 3). In addition, specific activity scale class
p  0.001) and self-reported health on a scale of 0 to 100
p  0.03) worsened significantly, compared with their
alues at the time of implantation. After crossover to
hysiologic pacing, 9 of the 10 SF-36 scales improved, and
improved significantly, as did scores on the specific activity
cale (p  0.02), the time tradeoff score (p  0.01), and the
elf-reported 0 to 100 scale (p  0.001; data based on 153
atients). The most striking improvements were in energy
nd physical role, both of which improved to become
ubstantially better than they were even before pacemaker
mplantation.
ISCUSSION
n the MOST study, a large, prospective study of individ-
als with sick sinus syndrome randomized to VVIR versus
DDR pacing, the life-table incidence of pacemaker syn-
rome was 13.8% at one year and 19.7% at four years. The
nly pre-implant clinical data and implant data that pre-
icted pacemaker syndrome were a lower sinus rate at
mplantation and a higher programmed pacemaker rate. In
ollow-up, a greater percentage of beats paced predicted the
evelopment of pacemaker syndrome, but this information
s of little use at the time of implantation in determining
hether a patient should receive a physiologic pacemaker.
ost notably, quality of life, as assessed by a variety of
etrics, decreased at the time of diagnosis of pacemaker
yndrome and improved after the pacemaker was repro-
rammed to a physiologic mode. (However, a placebo effect
annot be truly ruled out, because neither patients nor
hysicians were blinded to the crossover status.)
In other studies, the incidence of pacemaker syndrome
able 3. Quality of Life at Baseline, Prior to Crossover, and Afte
Mean and SD
at Baseline
N  153
Mean and SD
at Crossover
N  80 Ch
F-36
Physical–composite 35.8 (10.7) 33.3 (10.1) 2.3
Mental–composite 51.5 (9.5) 49.8 (10.9) 2.2
Physical–function 56.4 (27.6) 39.8 (28.1) 16.1
Role–physical 28.4 (38.7) 28.4 (39.3) 2.0
Pain 66.8 (29.1) 70.9 (24.7) 4.1
Health perception 57.2 (21.1) 52.4 (20.7) 4.4
Energy 39.6 (23.2) 32.1 (21.4) 6.6
Social–function 67.7 (24.7) 62.2 (26.5) 6.8
Role–emotional 80.4 (34.7) 75.4 (39.2) 9.6
Mental health 77.4 (17.2) 73.5 (19.6) 3.4
AS
1–4 SAS* 2.09 (0.93) 2.50 (0.91) 0.35
TO
0–1 TTO 0.75 (0.34) 0.73 (0.35) 0.034
–100 Scale 65.8 (19.8) 60.6 (20.0) 5.7
Higher score is worse. For Short Form (SF)-36, higher scores are better; for Specifi
re better; for 0–100 Scale, higher scores are better.as varied from 2% to as high as 83%, depending on the priteria by which pacemaker syndrome was diagnosed and
he therapy used to resolve that diagnosis (i.e., surgical
evision or reprogramming only) (1). In previous studies in
hich patients received VVIR pacemakers and thus re-
uired surgical revision to upgrade to physiologic pacing,
he incidence of pacemaker syndrome has been reported to
e quite low. In a Danish study published in 1994, 225
atients were randomized to VVIR versus atrial-based
acemakers; the incidence of pacemaker syndrome was
eported to be 2% (4). In the Canadian Trial of Physiologic
acing (CTOPP) published in 2000, in which surgical
evision was required to upgrade a patient from VVIR
acing to physiologic pacing, the incidence of pacemaker
yndrome was reported to be 2.7% at three years (12).
By contrast, in studies in which all patients received a
ual-chamber pacemaker and could have it reprogrammed,
he reported incidence of pacemaker syndrome has been
uch higher. For example, in the Pacemaker Selection in
he Elderly (PASE) study, the incidence of pacemaker
yndrome was 20% at six months (13). In the current study,
ll patients received a DDDR system, so crossover from
VIR to DDDR could be achieved relatively easily by
eprogramming without the need for a repeat surgical
rocedure. However, because pacemaker syndrome was
igorously defined prospectively and documented by
hanges in quality of life, the current study may more
ccurately reflect the incidence of pacemaker syndrome in
his population.
It is quite likely that differences in the incidence of
acemaker syndrome may largely be due to potential barriers
o diagnosis when surgical revision is necessary to resolve
he diagnosis. It is possible that subclinical pacemaker
yndrome may be present and undiagnosed in studies
hat require surgical revision to upgrade patients to a
ossover
and p Value
Mean and SD
After Crossover
N  136 Change and p Value
) p  0.17 38.0 (11.6) 3.8 (12.3) p  0.01
) p  0.09 52.7 (11.6) 2.5 (9.7) p  0.048
p  0.001 55.0 (29.7) 12.9 (29.0) p  0.001
) p  0.78 50.6 (43.0) 20 (51.7) p  0.003
) p  0.25 69.5 (26.3) 2.4 (28.7) p  0.57
) p  0.02 56.5 (21.5) 3.0 (16.0) p  0.14
) p  0.01 49.9 (24.5) 15.5 (27.0) p  0.001
) p  0.04 71.1 (24.1) 6.5 (30.2) p  0.04
) p  0.02 83.6 (32.9) 7.2 (39.2) p  0.11
) p  0.02 77.5 (17.8) 3.7 (16.6) p  0.13
) p  0.001 2.07 (0.94) 0.24 (0.88) p  0.02
) p  0.77 0.82 (0.31) 0.11 (0.36) p  0.01
) p  0.03 70.8 (19.5) 10.2 (25.2) p  0.001
ities Scale (SAS), lower scores are better; for Time Trade Off (TTO), higher scoresr Cr
ange
(10.8
(10.1
(27)
(52.8
(28.5
(17.0
(24.1
(29.2
(40.7
(15.0
(0.87
(0.31
(23.7
c Activhysiologic-based system (14,15). In one study, 16 patients
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June 2, 2004:2066–71 Pacemaker Syndrome in the MOST Studyith VVIR pacemakers were given atrial leads and random-
zed to ventricular demand pacing or physiologic pacing;
erceived well-being and exercise capacity were improved
uring physiologic pacing (14). This finding was confirmed
n 2001 in a similar study of 20 patients who had an atrial
ead placed at the time of generator replacement; stroke
olume and exercise capacity were increased in all individ-
als, and those with sick sinus syndrome had an improve-
ent in quality of life (15).
Finally, it is also possible that the greater percentage of
eats paced (which was predictive of the development of
acemaker syndrome in the current study) was lower in
hose studies that reported low frequencies of pacemaker
yndrome. In the CTOPP (12) and Danish (4) studies, the
ercentage of beats paced was not reported.
In our current investigation, patients with more severe
radycardia (lower resting sinus rates at implantation and a
igher percentage of paced beats at follow-up) were more
ikely to develop pacemaker syndrome. Similarly, in the
TOPP study, patients with a lower resting heart rate were
ore likely to benefit from physiologic pacing (16). In a
ecent publication from the MOST cohort, the percentage
f ventricular beats that were paced in patients randomized
o DDDR correlated with the risk of congestive heart failure
17). The finding that a higher percentage of VVIR beats
ncreases the risk of pacemaker syndrome and congestive
eart failure may be evidence that ventricular dyssynchrony
nduced by pacing one ventricle may cause pacemaker
yndrome, even in the presence of AV synchrony.
In elderly patients who receive pacemakers, physical
unction and quality of life generally improve quickly, while
radycardia is prevented, but then often decline because of
he progression of cardiac disease, the development or
rogression of co-morbid conditions, or even aging itself
7,11,13). In some patients who receive VVIR pacing,
owever, a more precipitous decline may represent pace-
aker syndrome. When this syndrome is suspected, careful
valuation is mandatory because atrial-based, physiologic
acing may markedly improve physical function and quality
f life. Because prediction of pacemaker syndrome is diffi-
ult, the only way to prevent the syndrome is to implant an
trial lead in all patients. Whether such an approach is
ost-effective will likely depend on the relative cost of the
lternative pacing modalities and the tradeoff between the
enefits of physiologic pacing and its association with a
horter battery life.eprint requests and correspondence: Dr. Mark S. Link, Tufts-
ew England Medical Center, Box #197, 750 Washington Street,
oston, Massachusetts 02111. E-mail: MLink@tufts-nemc.org.
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